Barinthus Biotherapeutics
1.03
0.05 (5.63%)
At close: Jan 14, 2025, 3:58 PM
0.95
-8.00%
After-hours Jan 14, 2025, 03:59 PM EST
undefined%
Bid 0.91
Market Cap 40.72M
Revenue (ttm) -
Net Income (ttm) -
EPS (ttm) -1.49
PE Ratio (ttm) -0.69
Forward PE n/a
Analyst Buy
Ask 1.3
Volume 22,867
Avg. Volume (20D) 51,932
Open 1.00
Previous Close 0.98
Day's Range 0.91 - 1.12
52-Week Range 0.80 - 4.16
Beta undefined

About BRNS

Barinthus Biotherapeutics plc, a clinical-stage biopharmaceutical company, engages in developing novel T cell immunotherapeutics to guide the immune system to overcome chronic infectious diseases, autoimmunity, and cancer. It is advancing a pipeline of product candidates across a range of therapeutic areas, including VTP-300, an immunotherapeutic candidate designed as a potential component of a functional cure for chronic HBV infection; VTP-200, ...

Industry Biotechnology
Sector Healthcare
IPO Date Apr 30, 2021
Employees 130
Stock Exchange NASDAQ
Ticker Symbol BRNS

Analyst Forecast

According to 2 analyst ratings, the average rating for BRNS stock is "Buy." The 12-month stock price forecast is $3, which is an increase of 191.29% from the latest price.

Buy 100.00%
Hold 0.00%
Sell 0.00%
Stock Forecasts
2 months ago · Source
+10.45%
Barinthus Biotherapeutics shares are trading highe... Unlock content with Pro Subscription
No News article available yet